Skip to main content

Luminex Acquires Automation Firm, Inks Microfluidics Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex today announced that it has acquired robotics and automation firm BSD Robotics and has inked an exclusive collaboration with a digital microfluidics firm.

The Austin, Texas-based firm celebrated the 10th anniversary of its Nasdaq listing by ringing the opening bell of the market and then held its Annual Investors Day. It announced the acquisition and alliance at that meeting.

Luminex said that the acquisition of BSD Robotics will provide it with new technologies in automation and robotics in the field of dry sample handling. The privately held Australian firm operates in several markets including newborn screening, forensics and human identification, and molecular diagnostics.

The firms did not disclose the acquisition price.

Luminex also announced an exclusive licensing agreement with Advanced Liquid Logic, under which the firms intend to co-develop new analytic systems and assays "that will help clinicians and scientists across several strategic markets deliver highly accurate results faster and more efficiently."

ALL was founded in 2004 to develop digital microfluidics technology from Duke University. The Morrisville, NC-based firm's technology enables liquid handling without pipes, pumps, or valves, with droplets being electrically manipulated. Luminex said that the digital microfluidics could be combined with its xMAP technology and three-dimensional liquid arrays to form a "very versatile sample preparation and assay development platform."

"By combining Liquid Logic's digital microfluidic technology with Luminex's xMAP technology, we can create smaller, more cost-efficient systems and very streamlined assays that require less hands-on time and provide very fast, accurate results," Advanced Liquid Logic CEO Richard West said in a statement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.